Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine

Lignende værker

• Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
  af: Alexander S. Hölscher, et al.
  Udgivet: (2018-01-01)
• Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
  af: Hölscher, Alexander S., et al.
  Udgivet: (2018)
• Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
  af: Pinkerneil, Maria, et al.
  Udgivet: (2016)
• Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
  af: Sausville, Edward, et al.
  Udgivet: (2014)
• Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling
  af: Wang, Luqi, et al.
  Udgivet: (2018)